FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.”

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays Clinical Trials 64

Predictive Oncology

AUGUST 8, 2024

A recent white paper released by Predictive Oncology’s highlights the challenge of late-stage clinical trial failures and the company’s ability to better navigate those obstacles and increase the probability of technical success which is a key metric in target selection, clinical trial design and pipeline replenishment.

Drug Development 52

Drug Development Clinical Trials Animal Testing Trials 52

FDA Law Blog: Drug Discovery

SEPTEMBER 27, 2023

The draft guidance helpfully adds a few examples of appropriate Type D meeting scenarios, and they are: A specific question about an aspect of a complex or innovative trial design (e.g.,

FDA 64

FDA Packaging Animal Testing Production 64

Codon

JUNE 2, 2024

This discordance, or lack of “ predictive validity ” when translating results across organismal boundaries, is perhaps most harmful in the biomedical field; despite extensive testing in mouse models, only 10 percent of drugs that make it to clinical trials ever make it to market. Cite this essay: Alex Telford.

Laboratories 130

Laboratories Research Disease Science 130

Codon

MARCH 14, 2023

The ALS Therapy Development Institute, located just ten minutes from my home in Cambridge, once tested more than 100 potential drugs to slow ALS progression in mice, all of which had been reported to be helpful in other studies. Each animal had a different microbiome. Free-range mice? .” A third experiment found no effect.

DNA 52

DNA Laboratories Engineering Animal Testing 52

FDA Law Blog: Drug Discovery

DECEMBER 6, 2024

Instead, this guidance highlights questions about species, animal model, and product selection for nonclinical programs as well as several aimed at helping to understand the purpose and importance of POC, toxicity, and biodistribution studies. Stay tuned for the next iteration of the Cliffs Notes to the Cliffs Notes.

Therapies 59

Therapies FDA Production Disease 59